Insmed Stock News & Updates
[WKN: A1JJA3 | Symbol: INSM]
Buy-the-Dip Buyers Stop Wall Street Slide – Iran Conflict Drives Oil Price to $108 – Stagflation Risks Burden Markets – Week Ahead: All Eyes on the Labor Market – McDonald's Launches KPop Demon Hunters Menu - United Therapeutics Achieves Study Success - Aluminum World Market in Turmoil
USA & MACRO ENVIRONMENT Wall Street ends a turbulent phase with an initial counter-movement:...
Insmed Dominates the Respiratory Market – Revenue Expected to More Than Double by 2026!
Insmed (INSM) has specialized as a biopharmaceutical company in the development and marketing of therapies...
Analysts' Top 5 Price Targets of March 30, 2026
Jenoptik [DE000A2NB601] Deutsche Bank reiterates Buy rating and raises the price target from €28...
Geopolitical Shift Propels Global Markets – Trump Suspends Iran Strikes, DAX Turns Spectacularly Positive – Fed Balances Inflation and War Risks – Elliott Targets Synopsys – Tesla is Planning its own Chip Factories - Teradyne Positions Itself in the AI Boom - DraftKings Benefits from Regulatory Boost
USA & MACRO-OUTLOOK Wall Street on the rise: Geopolitics trump recession fears The US stock...
Insmed's Masterpiece: From Niche Player to Billion-Dollar Heavyweight
Insmed (i.) is a pharmaceutical company that specializes in the development of medications for people...
Insmed: Double Strike in Rare Lung Diseases Unleashes New Billion-Dollar Potential
Insmed Inc. (INSM) is a biotechnology company specializing in therapies for severe and rare diseases....
Stocks in Action USA: Insmed, D.R. Horton, Oklo
Insmed (INSM) – Revenue Explosion from New Drug "Brinsupri": Biotech Specialist on the Cusp of a Decisive...
US Markets Friendly - Unemployment Rate Slightly Decreases - DAX at Record Level - Double Upgrade for Southwest Airlines - Trump's Mortgage Bond Plan Boosts Homebuilding Stocks - Merger Talks Between Rio Tinto and Glencore - Meta's Nuclear Energy Agreements Drive Utility Stocks
Wall Street p robes a head – l abor m arket s upports r ate p ause f antasy The US stock...
Insmed Secures EU Approval for Brensocatib – First Indication Offers Peak Revenue Potential of $5 Billion!
The biotech company Insmed (INSM) specializes in the development of medications for the treatment of...
The Stock of Insmed Consolidates the Strong Q3 Results and is Poised for the Trend Continuation!
Insmed is a biopharmaceutical company focused on the development and marketing of therapies for patients...
5 Rising Biopharma Stocks with over 50% Annual Growth Potential
Dear readers, Last week, I introduced five biopharma stocks that have taken off in recent weeks. It...